Can-Fite BioPharma Ltd. has made a significant advancement in its drug development efforts by securing a patent allowance from the Eurasian Patent Office for its drug Piclidenoson. This drug is aimed at treating Lowe syndrome, a rare genetic disorder. This patent allowance is crucial as it strengthens the company’s intellectual property position and supports its future commercialization strategies.

On November 2, 2026, Can-Fite BioPharma, listed on the NYSE under the ticker CANF, announced the patent allowance in a press release. The company specializes in developing proprietary small molecule drugs to address oncological and inflammatory diseases. This recent development is particularly important as it positions Can-Fite to capitalize on the growing market for treatments targeting rare diseases.

The patent covers the use of Piclidenoson for diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2. The allowance is a result of Can-Fite's collaboration with Fondazione Telethon, which owns the patent application. Under their agreement, Can-Fite holds the rights to develop, commercialize, and out-license Piclidenoson for Lowe syndrome.

According to the filing, the allowance of the patent is a significant milestone that strengthens Can-Fite's development program and opens up future partnering opportunities in this therapeutic area. Motti Farbstein, CEO of Can-Fite, stated, “This patent allowance strengthens the intellectual property foundation of our Lowe syndrome program and supports its long-term commercial potential.”

Lowe syndrome is characterized by severe renal, neurological, and ocular manifestations caused by mutations in the OCRL gene. Currently, there are no approved therapies addressing the underlying disease mechanisms, making Can-Fite's development of Piclidenoson particularly timely and relevant.

The Phase 2 clinical trial for Piclidenoson is designed to evaluate its efficacy and safety in adult patients with genetically confirmed Lowe syndrome. The primary endpoint of the trial is to measure improvements in renal function, which is critical for patients suffering from this debilitating disease.

This patent allowance could potentially impact various stakeholders, including patients with Lowe syndrome, healthcare providers, and investors in the pharmaceutical preparations industry. As Can-Fite moves forward with its development plans, it may also face competition from other companies exploring similar therapeutic avenues in rare diseases.

The filing does not specify what happens next in terms of regulatory approvals or additional clinical trials for Piclidenoson. However, the company is expected to continue its efforts in advancing this promising treatment for patients in need.